James Stocks

3.2k total citations · 1 hit paper
31 papers, 1.4k citations indexed

About

James Stocks is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, James Stocks has authored 31 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 13 papers in Cancer Research and 5 papers in Molecular Biology. Recurrent topics in James Stocks's work include Protease and Inhibitor Mechanisms (13 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (9 papers) and Blood Coagulation and Thrombosis Mechanisms (5 papers). James Stocks is often cited by papers focused on Protease and Inhibitor Mechanisms (13 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (9 papers) and Blood Coagulation and Thrombosis Mechanisms (5 papers). James Stocks collaborates with scholars based in United States, Ireland and Canada. James Stocks's co-authors include Robert A. Sandhaus, Brian Tiep, Rick Carter, David B. Holiday, Charlie Strange, Mark Brantly, Carol Grothues, Chiagozie Nwasuruba, Noel G. McElvaney and James K. Stoller and has published in prestigious journals such as The Lancet, CHEST Journal and European Respiratory Journal.

In The Last Decade

James Stocks

31 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial

2015 325 citations Kenneth R. Chapman, Jonathan Burdon et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Stocks United States	18	714	529	500	299	213	31	1.4k
Richard Brasington United States	22	398 0.6×	44 0.1×	146 0.3×	170 0.6×	195 0.9×	41	1.7k
Feng Tao China	17	179 0.3×	248 0.5×	415 0.8×	198 0.7×	36 0.2×	36	1.3k
Kun‐Yun Yeh Taiwan	24	302 0.4×	162 0.3×	777 1.6×	296 1.0×	19 0.1×	125	1.6k
Rachel Conyers Australia	17	253 0.4×	92 0.2×	337 0.7×	26 0.1×	37 0.2×	56	927
Theodore T. Suh United States	14	199 0.3×	200 0.4×	116 0.2×	71 0.2×	386 1.8×	23	1.0k
Wanqing Iris Zhi United States	16	221 0.3×	178 0.3×	585 1.2×	88 0.3×	30 0.1×	40	1.2k
Trevor A. Jolly United States	14	252 0.4×	74 0.1×	460 0.9×	314 1.1×	29 0.1×	32	953
Andrea Mambrini Italy	22	453 0.6×	191 0.4×	829 1.7×	25 0.1×	19 0.1×	109	1.5k
Eun‐Kee Song South Korea	22	380 0.5×	120 0.2×	623 1.2×	43 0.1×	80 0.4×	80	1.4k
Julia B. Greer United States	26	178 0.2×	133 0.3×	892 1.8×	78 0.3×	62 0.3×	48	1.9k

Countries citing papers authored by James Stocks

Since Specialization

Citations

This map shows the geographic impact of James Stocks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Stocks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Stocks more than expected).

Fields of papers citing papers by James Stocks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Stocks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Stocks. The network helps show where James Stocks may publish in the future.

Co-authorship network of co-authors of James Stocks

This figure shows the co-authorship network connecting the top 25 collaborators of James Stocks. A scholar is included among the top collaborators of James Stocks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Stocks. James Stocks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brantly, Mark, James Stocks, Jorge Lascano, et al.. (2024). Inhaled alpha-1 antitrypsin (AAT) restores lower respiratory tract protease–antiprotease homoeostasis and reduces inflammation in AAT-deficient individuals: a randomised phase 2 study. ERJ Open Research. 11(1). 537–2024. 3 indexed citations

Cantor, Jerome, Shuren Ma, Xingjian Liu, et al.. (2021). A 28-day clinical trial of aerosolized hyaluronan in alpha-1 antiprotease deficiency COPD using desmosine as a surrogate marker for drug efficacy. Respiratory Medicine. 182. 106402–106402. 13 indexed citations

Sandhaus, Robert A., Gerard Turino, Mark Brantly, et al.. (2016). The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 3(3). 668–682. 140 indexed citations

Chapman, Kenneth R., Jonathan Burdon, Eeva Piitulainen, et al.. (2015). Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. The Lancet. 386(9991). 360–368. 325 indexed citations breakdown →

Sandhaus, Robert A., Kenneth R. Chapman, Jonathan Burdon, et al.. (2014). Integrated safety across six clinical trials of alpha-1 augmentation therapy. European Respiratory Journal. 44(Suppl 58). P950–P950. 2 indexed citations

Stocks, James, Robert A. Sandhaus, Kenneth R. Chapman, et al.. (2014). Baseline Patient Demographics and Lung Density Decline in the RAPID Trial. CHEST Journal. 146(4). 71A–71A. 1 indexed citations

Campos, Michael, Friedrich Kueppers, James Stocks, et al.. (2013). Safety and Pharmacokinetics of 120 mg/kg versus 60 mg/kg Weekly Intravenous Infusions of Alpha-1 Proteinase Inhibitor in Alpha-1 Antitrypsin Deficiency: A Multicenter, Randomized, Double-Blind, Crossover Study (SPARK). COPD Journal of Chronic Obstructive Pulmonary Disease. 10(6). 687–695. 44 indexed citations

Sandhaus, Robert A., et al.. (2013). Biochemical Efficacy and Safety of a New, Ready-to-Use, Liquid Alpha-1-Proteinase Inhibitor, GLASSIA (Alpha ₁ -Proteinase Inhibitor (Human), Intravenous). COPD Journal of Chronic Obstructive Pulmonary Disease. 11(1). 17–25. 15 indexed citations

Siedliński, Mateusz, Barbara J. Klanderman, Robert A. Sandhaus, et al.. (2012). Association of cigarette smoking and CRP levels with DNA methylation in α-1 antitrypsin deficiency. Epigenetics. 7(7). 720–728. 20 indexed citations

10.

Kim, Woo Jin, Alice M. Wood, Alan F. Barker, et al.. (2012). Association of IREB2 and CHRNA3polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. Respiratory Research. 13(1). 16–16. 36 indexed citations

11.

Stocks, James, Mark Brantly, Michael Campos, et al.. (2010). Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha1-antitrypsin deficiency: a randomized study. PubMed. 10(1). 13–13. 29 indexed citations

12.

Sandhaus, Robert A., Gerard Turino, James Stocks, et al.. (2008). α1-Antitrypsin Augmentation Therapy for PI*MZ Heterozygotes. CHEST Journal. 134(4). 831–834. 36 indexed citations

13.

DeMeo, Dawn L., Edward J. Campbell, Alan F. Barker, et al.. (2007). IL10 Polymorphisms Are Associated with Airflow Obstruction in Severe α1-Antitrypsin Deficiency. American Journal of Respiratory Cell and Molecular Biology. 38(1). 114–120. 61 indexed citations

14.

Stocks, James, Mark Brantly, Alan R. Barker, et al.. (2006). Multi-Center Study: The Biochemical Efficacy, Safety and Tolerability of a New α₁-Proteinase Inhibitor, Zemaira. COPD Journal of Chronic Obstructive Pulmonary Disease. 3(1). 17–23. 40 indexed citations

15.

Stocks, James, Mark Brantly, Alan R. Barker, et al.. (2005). COMPARABLE PHARMACOKINETIC PROPERTIES OF TWO ALPHA1-PROTEINASE INHIBITORS AFTER SINGLE THERAPEUTIC DOSES. CHEST Journal. 128(4). 261S–261S. 2 indexed citations

16.

Spencer, L. Terry, et al.. (2005). LOWER RESPIRATORY TRACT BIOCHEMICAL EFFICACY OF INTRAVENOUS ADMINISTRATION OF A NEW FORM OF HIGHLY PURIFIED ALPHA1-ANTITRYPSIN. CHEST Journal. 128(4). 261S–261S. 1 indexed citations

17.

Carter, Rick, David B. Holiday, James Stocks, & Brian Tiep. (2003). Peak Physiologic Responses to Arm and Leg Ergometry in Male and Female Patients With Airflow Obstruction*. CHEST Journal. 124(2). 511–518. 24 indexed citations

18.

Carter, Rick, David B. Holiday, Chiagozie Nwasuruba, et al.. (2003). 6-Minute Walk Work for Assessment of Functional Capacity in Patients With COPD. CHEST Journal. 123(5). 1408–1415. 170 indexed citations

19.

Carter, Rick, David B. Holiday, Carol Grothues, et al.. (2002). Criterion Validity of the Duke Activity Status Index for Assessing Functional Capacity in Patients With Chronic Obstructive Pulmonary Disease. Journal of Cardiopulmonary Rehabilitation. 22(4). 298–308. 69 indexed citations

20.

Stoller, James K., Farshid N. Rouhani, Mark Brantly, et al.. (2002). Biochemical Efficacy and Safety of a New Pooled Human Plasma α1-Antitrypsin, Respitin. CHEST Journal. 122(1). 66–74. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact